Cutera Stock Forecast, Price & News

Cutera (NASDAQ:CUTR) Frequently Asked Questions

Is Cutera a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cutera stock.
View analyst ratings for Cutera or view top-rated stocks.

How has Cutera's stock been impacted by COVID-19?

Cutera's stock was trading at $18.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CUTR stock has increased by 92.9% and is now trading at $34.94.
View which stocks have been most impacted by COVID-19.

When is Cutera's next earnings date?

Cutera is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for Cutera.

How were Cutera's earnings last quarter?

Cutera, Inc. (NASDAQ:CUTR) issued its quarterly earnings results on Wednesday, November, 3rd. The medical device company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.11. The medical device company had revenue of $57.38 million for the quarter, compared to analyst estimates of $50.90 million. Cutera had a trailing twelve-month return on equity of 15.80% and a net margin of 3.80%. During the same period last year, the firm posted ($0.13) EPS.
View Cutera's earnings history.

What guidance has Cutera issued on next quarter's earnings?

Cutera updated its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $224 million-$228 million, compared to the consensus revenue estimate of $218.82 million.

What price target have analysts set for CUTR?

3 equities research analysts have issued 12 month price objectives for Cutera's stock. Their forecasts range from $60.00 to $65.00. On average, they expect Cutera's share price to reach $61.67 in the next twelve months. This suggests a possible upside of 76.5% from the stock's current price.
View analysts' price targets for Cutera or view top-rated stocks among Wall Street analysts.

Who are Cutera's key executives?

Cutera's management team includes the following people:

• David H. Mowry, Chief Executive Officer & Director
• Rohan Seth, Chief Financial Officer
• Michael Karavitis, Chief Technology Officer & Executive VP
• Jeremy Livianu, Secretary, Vice President & General Counsel
• Anne Werdan, Director-Investor Relations

What is David H. Mowry's approval rating as Cutera's CEO?

1 employees have rated Cutera CEO David H. Mowry on Glassdoor.com. David H. Mowry has an approval rating of 100% among Cutera's employees. This puts David H. Mowry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cutera's key competitors?

Some companies that are related to Cutera include Outset Medical (OM), BioLife Solutions (BLFS), Natus Medical (NTUS), ViewRay (VRAY), Semler Scientific (SMLR), TransMedics Group (TMDX), Stereotaxis (STXS), AxoGen (AXGN), Zynex (ZYXI), Edap Tms (EDAP), Electromed (ELMD), Movano (MOVE), FONAR (FONR), IRIDEX (IRIX) and BioSig Technologies (BSGM).
View all of CUTR's competitors.

What other stocks do shareholders of Cutera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cutera investors own include NVIDIA (NVDA), QUALCOMM (QCOM), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), DocuSign (DOCU), Pfizer (PFE), Square (SQ) and Twilio (TWLO).

What is Cutera's stock symbol?

Cutera trades on the NASDAQ under the ticker symbol "CUTR."

Who are Cutera's major shareholders?

Cutera's stock is owned by many different institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.06%) and Future Financial Wealth Managment LLC (0.01%). Company insiders that own Cutera stock include David H Mowry, J Daniel Plants, Joseph E Whitters, Katherine S Zanotti, Rohan Seth and Timothy J Oshea.
View institutional ownership trends for Cutera.

Which major investors are selling Cutera stock?

CUTR stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Cutera or view top insider-selling stocks.

Which major investors are buying Cutera stock?

CUTR stock was bought by a variety of institutional investors in the last quarter, including Future Financial Wealth Managment LLC. Company insiders that have bought Cutera stock in the last two years include David H Mowry, J Daniel Plants, Joseph E Whitters, Katherine S Zanotti, Rohan Seth, and Timothy J Oshea.
View insider buying and selling activity for Cutera or or view top insider-buying stocks.

How do I buy shares of Cutera?

Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cutera's stock price today?

One share of CUTR stock can currently be purchased for approximately $34.94.

How much money does Cutera make?

Cutera has a market capitalization of $627.42 million and generates $147.68 million in revenue each year. The medical device company earns $-23.88 million in net income (profit) each year or $0.41 on an earnings per share basis.

How many employees does Cutera have?

Cutera employs 323 workers across the globe.

When was Cutera founded?

Cutera was founded in 1998.

What is Cutera's official website?

The official website for Cutera is www.cutera.com.

Where are Cutera's headquarters?

Cutera is headquartered at 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005.

How can I contact Cutera?

Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at (415) 657-5500, via email at [email protected], or via fax at 415-330-2444.